Jundishapur Journal of Microbiology

Published by: Kowsar

In Vitro Activity of Caspofungin Against Fluconazole-Resistant Candida Species Isolated From Clinical Samples in Iran

Hamideh Shekari Ebrahim Abad 1 , Farideh Zaini 1 , * , Parivash Kordbacheh 1 , Mahmoud Mahmoudi 2 , Mahin Safara 1 and Vida Mortezaee 1
Authors Information
1 Department of Parasitology and Mycology, School of Public Health, Institute of Public Health Researches, Tehran University of Medical Sciences, Tehran, IR Iran
2 Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, IR Iran
Article information
  • Jundishapur Journal of Microbiology: June 2015, 8 (6); e59871
  • Published Online: June 27, 2015
  • Article Type: Research Article
  • Received: February 19, 2014
  • Revised: June 16, 2014
  • Accepted: July 20, 2014
  • DOI: 10.5812/jjm.18353v2

To Cite: Shekari Ebrahim Abad H, Zaini F, Kordbacheh P, Mahmoudi M, Safara M, et al. In Vitro Activity of Caspofungin Against Fluconazole-Resistant Candida Species Isolated From Clinical Samples in Iran, Jundishapur J Microbiol. 2015 ; 8(6):e59871. doi: 10.5812/jjm.18353v2.

Copyright © 2015, Ahvaz Jundishapur University of Medical Sciences.This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Materials and Methods
4. Results
5. Discussion
  • 1. Hoehamer CF, Cummings ED, Hilliard GM, Rogers PD. Changes in the proteome of Candida albicans in response to azole, polyene, and echinocandin antifungal agents. Antimicrob Agents Chemother. 2010; 54(5): 1655-64[DOI][PubMed]
  • 2. Lemos J, Costa CR, Araújo C, Souza LKH, Silva M. Susceptibility testing of Candida albicans isolated from oropharyngeal mucosa of HIV+ patients to fluconazole, amphotericin B and Caspofungin: killing kinetics of caspofungin and amphotericin B against fluconazole resistant and susceptible isolates. Brazilian J Microbiol. 2009; 40(1): 163-9[DOI]
  • 3. Chattopadhyay A, Caplan DJ, Slade GD, Shugars DC, Tien HC, Patton LL. Risk indicators for oral candidiasis and oral hairy leukoplakia in HIV-infected adults. Community Dent Oral Epidemiol. 2005; 33(1): 35-44[DOI][PubMed]
  • 4. Garnacho-Montero J, Diaz-Martin A, Ruiz-Perez De Piappon M, Garcia-Cabrera E. [Invasive fungal infection in critically ill patients]. Enferm Infecc Microbiol Clin. 2012; 30(6): 338-43[DOI][PubMed]
  • 5. Majoros L, Kardos G, Szabo B, Sipiczki M. Caspofungin susceptibility testing of Candida inconspicua: correlation of different methods with the minimal fungicidal concentration. Antimicrob Agents Chemother. 2005; 49(8): 3486-8[DOI][PubMed]
  • 6. Bachmann SP, Patterson TF, Lopez-Ribot JL. In vitro activity of caspofungin (MK-0991) against Candida albicans clinical isolates displaying different mechanisms of azole resistance. J Clin Microbiol. 2002; 40(6): 2228-30[PubMed]
  • 7. Barchiesi F, Schimizzi AM, Fothergill AW, Scalise G, Rinaldi MG. In vitro activity of the new echinocandin antifungal, MK-0991, against common and uncommon clinical isolates of Candida species. Eur J Clin Microbiol Infect Dis. 1999; 18(4): 302-4[PubMed]
  • 8. Posteraro B, Sanguinetti M, Fiori B, La Sorda M, Spanu T, Sanglard D, et al. Caspofungin activity against clinical isolates of azole cross-resistant Candida glabrata overexpressing efflux pump genes. J Antimicrob Chemother. 2006; 58(2): 458-61[DOI][PubMed]
  • 9. Nagappan V, Boikov D, Vazquez JA. Assessment of the in vitro kinetic activity of caspofungin against Candida glabrata. Antimicrob Agents Chemother. 2010; 54(1): 522-5[DOI][PubMed]
  • 10. Bartizal C, Odds FC. Influences of methodological variables on susceptibility testing of caspofungin against Candida species and Aspergillus fumigatus. Antimicrob Agents Chemother. 2003; 47(7): 2100-7[PubMed]
  • 11. Pfaller MA, Messer SA, Boyken L, Rice C, Tendolkar S, Hollis RJ, et al. Caspofungin activity against clinical isolates of fluconazole-resistant Candida. J Clin Microbiol. 2003; 41(12): 5729-31[PubMed]
  • 12. Rex JH, Rinaldi MG, Pfaller MA. Resistance of Candida species to fluconazole. Antimicrob Agents Chemother. 1995; 39(1): 1-8[PubMed]
  • 13. Jabra-Rizk MA, Falkler WA, Meiller TF. Fungal biofilms and drug resistance. Emerg Infect Dis. 2004; 10(1): 14-9[DOI][PubMed]
  • 14. Enwuru CA, Ogunledun A, Idika N, Enwuru NV, Ogbonna F, Aniedobe M, et al. Fluconazole resistant opportunistic oro-pharyngeal Candida and non-Candida yeast-like isolates from HIV infected patients attending ARV clinics in Lagos, Nigeria. Afr Health Sci. 2008; 8(3): 142-8[PubMed]
  • 15. Lewis RE, Klepser ME, Pfaller MA. Update on clinical antifungal susceptibility testing for Candida species. Pharmacotherapy. 1998; 18(3): 509-15[PubMed]
  • 16. Badiee P, Alborzi A, Davarpanah MA, Shakiba E. Distributions and antifungal susceptibility of Candida species from mucosal sites in HIV positive patients. Arch Iran Med. 2010; 13(4): 282-7[PubMed]
  • 17. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts. 2008;
  • 18. Denning DW. Echinocandins: a new class of antifungal. J Antimicrob Chemother. 2002; 49(6): 889-91[PubMed]
  • 19. reference method for broth dilution antifungal susceptibility testing at yeasts: approved standard 2002;
  • 20. Fera MT, La Camera E, De Sarro A. New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance. Expert Rev Anti Infect Ther. 2009; 7(8): 981-98[DOI][PubMed]
  • 21. Mortezaee V, Zaini F, Kordbacheh P, Mahmoudi M, Safara M, Shekari H. In vitro Susceptibilities of Iranian Clinical non-albicans Candida species to Caspofungin and Ketoconazole. J Basic Appl Sci Res. 2012; 2(2): 1608-14
  • 22. Pfaller MA, Messer SA, Boyken L, Tendolkar S, Hollis RJ, Diekema DJ. Variation in susceptibility of bloodstream isolates of Candida glabrata to fluconazole according to patient age and geographic location. J Clin Microbiol. 2003; 41(5): 2176-9[PubMed]
  • 23. Rex JH, Walsh TJ, Sobel JD, Filler SG, Pappas PG, Dismukes WE, et al. Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America. Clin Infect Dis. 2000; 30(4): 662-78[DOI][PubMed]
  • 24. Pfaller MA, Diekema DJ, Messer SA, Boyken L, Hollis RJ, Jones RN, et al. In vitro activities of voriconazole, posaconazole, and four licensed systemic antifungal agents against Candida species infrequently isolated from blood. J Clin Microbiol. 2003; 41(1): 78-83[PubMed]
  • 25. Bartizal K, Gill CJ, Abruzzo GK, Flattery AM, Kong L, Scott PM, et al. In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872). Antimicrob Agents Chemother. 1997; 41(11): 2326-32[PubMed]
  • 26. Ernst EJ, Klepser ME, Ernst ME, Messer SA, Pfaller MA. In vitro pharmacodynamic properties of MK-0991 determined by time-kill methods. Diagn Microbiol Infect Dis. 1999; 33(2): 75-80[PubMed]
  • 27. Ernst EJ, Klepser ME, Pfaller MA. Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans. Antimicrob Agents Chemother. 2000; 44(4): 1108-11[PubMed]
  • 28. Ernst ME, Klepser ME, Wolfe EJ, Pfaller MA. Antifungal dynamics of LY 303366, an investigational echinocandin B analog, against Candida ssp. Diagn Microbiol Infect Dis. 1996; 26(3-4): 125-31[PubMed]
  • 29. Martinez-Suarez JV, Rodriguez-Tudela JL. In vitro activities of semisynthetic pneumocandin L-733,560 against fluconazole-resistant and -susceptible Candida albicans isolates. Antimicrob Agents Chemother. 1996; 40(5): 1277-9[PubMed]
  • 30. Nelson PW, Lozano-Chiu M, Rex JH. In vitrogrowth-inhibitory activity of pneumocandins L-733,560 and L-743,872 against putatively amphotericin B- and fluconazole-resistantCandidaisolates: influence of assay conditions. Med Mycol. 1997; 35(4): 285-7[DOI]
  • 31. Lyon GM, Karatela S, Sunay S, Adiri Y, Candida Surveillance Study I. Antifungal susceptibility testing of Candida isolates from the Candida surveillance study. J Clin Microbiol. 2010; 48(4): 1270-5[DOI][PubMed]
  • 32. Silver PM, Oliver BG, White TC. Characterization of caspofungin susceptibilities by broth and agar in Candida albicans clinical isolates with characterized mechanisms of azole resistance. Med Mycol. 2008; 46(3): 231-9[DOI][PubMed]
  • 33. Pfaller MA, Diekema DJ, Messer SA, Hollis RJ, Jones RN. In vitro activities of caspofungin compared with those of fluconazole and itraconazole against 3,959 clinical isolates of Candida spp., including 157 fluconazole-resistant isolates. Antimicrob Agents Chemother. 2003; 47(3): 1068-71[PubMed]
  • 34. Ortiz de la Tabla-Ducasse V, Masia-Canuto M, Martin-Gonzalez C, Gutierrez-Rodero F. [In vitro activity of caspofungin against fluconazole-resistant Candida isolates from patients with HIV infection]. Enferm Infecc Microbiol Clin. 2004; 22(6): 328-31[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments